Prior studies of association between influenza virus with CF pulmonary exacerbations did not necessarily prove causation. Most evidence comes from small surveillance studies insufficiently powered to demonstrate a clinically meaningful association between respiratory viruses and CF morbidity [10] [11] [12] , or from ecological studies that fail to adjust for individual patient risks [20] . Our objective was to determine the population-level effect that seasonal influenza and RSV independently have on risk of serious pulmonary exacerbations in children and adults with CF in the United States. We hypothesized that regional seasonal influenza and RSV activity would be independently associated with increased risk of pulmonary exacerbations.
METHODS

Study Population
The CF Foundation Patient Registry (CFFPR) is a population-based registry of all consenting CF patients in the United States. It contains longitudinal encounter-based data relating to demographic, clinical, and socioeconomic parameters [1, 2] . Since 2003, encounter-based data are collected at each outpatient clinical assessment, during outpatient antibiotic therapy administration, during hospitalizations, and at annual reviews of patients followed at accredited CF centers (>115). In a 2012 CFFPR audit, patient data were highly accurate, and >90% of clinical visits and hospitalizations were documented [1] . Of an estimated 33 292-34 327 individuals with CF in the United States in 2012, the most recent year with available birth and mortality data, 81%-84% of these patients were captured by the registry [2] . Our study included individuals with CF in the CFFPR from 2003 to 2009 merged on a temporal and geographic basis with the US Centers for Disease Control and Prevention (CDC) virologic surveillance data on influenza and RSV tests performed and positive detections [21, 22] . As the CFFPR represents a dynamic cohort, baseline characteristics for the study cohort were from the 2003 annual review. The study was approved by the research ethics board at the University of Washington (institutional review board 18243) and the CF Foundation Patient Registry Committee.
Exposure Assessment
We accessed influenza surveillance data from the United StatesWorld Health Organization (WHO) Collaborating Laboratories and National Respiratory and Enteric Virus Surveillance System (NREVSS) Laboratories from the CDC website (www. cdc.gov/surveillance/nrevss) [23] . We acquired RSV data from NREVSS by a data use request [22] . For influenza, all state public health laboratories, in addition to some county public health laboratories and some large tertiary-care medical centers, participate as WHO collaborating laboratories (http://www.cdc. gov/flu/weekly/fluactivitysurv.htm). The participating laboratories directly report the total numbers of tested and positive specimens by reverse-transcription polymerase chain reaction (RT-PCR) for influenza types A and B on a weekly basis to the CDC [24] . Most WHO collaborating laboratories report influenza A subtype information but do not distinguish influenza B lineage. Data linkage to individuals including clinical or epidemiologic data is not available. The NREVSS is a laboratory-based surveillance system operating on a voluntary basis to collect weekly numbers of tested and positive specimens for RSV and other respiratory or enteric viruses [22] . During the study period from January 2003 through March 2009, laboratories reporting RSV results by antigen detection for ≥30 weeks and averaging ≥10 weekly specimens were included in the analysis [22] . The majority of NREVSS reporting laboratories (85%-90%) are hospital-based laboratories, with the remainder comprised of commercial and public health laboratories.
Influenza and RSV surveillance data were collected on a weekly basis, and were aggregated by 9 census districts and 4 census regions, respectively [22, 23] . Previously, we have shown that CDC influenza surveillance data are highly correlated with other influenza surveillance systems [25] . We calculated the relative proportions of positive specimens by week for influenza (by type and subtype) and RSV. We linked CF-associated pulmonary exacerbation data collected at a subject level on the basis of calendar week and geographic influenza (US Census District) and RSV (US Census Region) surveillance data. As we aimed to determine the association between seasonal influenza activity and pulmonary exacerbations, we ended our study period in March 2009 to avoid the 2009 influenza A(H1N1) pandemic.
Primary Outcome
All persons in the CFFPR during the study period were included for analysis and were considered present for an entire calendar year if they underwent annual review. The primary outcome was a documented CF pulmonary exacerbation requiring home intravenous antibiotic therapy or hospitalization. If an individual had duplicate pulmonary exacerbation events in the same week, or if 2 or more events were spaced within 1 month apart, these were counted as 1 event.
Statistical Analysis
We summarized continuous data using mean and standard deviation (SD) and categorical data using percentages. We categorized patients based on age (time-varying) at year end: <18 years and ≥18 years of age. We calculated incidence rates by dividing the number of exacerbation events by the total person-time of follow-up in the study period. Additionally, we calculated the proportion of patients with the number of annual exacerbation events by categorizing exacerbations (0/1, 2/3, 4/≥5) in a 12-month period.
We estimated the effect of influenza and RSV activity on the risk of CF pulmonary exacerbations by multivariate Poisson regression models adjusted for demographic and clinical covariates. We determined covariates a priori based on literature review of risk factors associated with CF pulmonary exacerbations [9, 26] . Covariates included temporal adjustment (quartic polynomial of year as well as sin and cos of 2π*year), age (as continuous), sex, race (white, African American, other or unknown), CF genotype (heterozygous, homozygous, and other/unknown), insurance status (private, government, none) and pancreatic insufficiency. Sensitivity analysis models adjusted for median household income (based on the average of the 2000 and 2010 zip code of patient residence, per $10 000 of income), body mass index (BMI) (as a percentile for children and value for adults) and FEV 1 % predicted (based on Wang and Hankinson) [27, 28] , in addition to the covariates in the primary model. For weeks with no BMI, FEV 1 % predicted or pancreatic insufficiency values recorded, we used the values from the last week with available data (ie, the last observation carried forward method). FEV 1 % predicted values from weeks with a pulmonary exacerbation were ignored. The influenza and RSV predictors were used with a 2-week lag (ie, exposure 2 weeks prior to the outcome week). The Poisson models were fitted using the R package biglm for the estimation of generalized linear models in large data sets [29] . We calculated the standard errors for the model coefficients using the nonparametric bootstrap by patient (50 resamples) to account for the repeated measures by patient and for potential overdispersion. All P values were 2-sided and P < .05 was considered statistically significant. Analyses were performed with Stata 13.1 (StataCorp, College Station, Texas), SAS 9.3 (SAS Institute, Cary, North Carolina), and R 3.2.5 [30] software.
RESULTS
Baseline Cohort Characteristics
In 2003, there were a total of 21 022 patients (48.2% female) of mean age 17.1 (SD, 11.9) years in the CFFPR meeting our inclusion criteria (Table 1) . Of these, 12 702 were children (48.9% female), and 8 320 were adults aged ≥18 years (47.0% female). The majority of the cohort was of white race (90.1%), had medical insurance (private or health maintenance organization) (64.1%), and had a median income by residence location of $42 659. Both adults and children had a median of 4 clinical encounters and a median of zero hospitalizations for a pulmonary exacerbation. Adults had a lower mean lung function measured as %FEV 1 predicted (60% vs 86%), and increased prevalence of P. aeruginosa (82% vs 48%) and B. cepacia complex (4% vs 2%) infection but lower prevalence of Staphylococcus aureus infection (42% vs 61%) than children in the patient cohort. Overall, 45% of the patients were delta-F508 homozygous, 34% were delta-F508 heterozygous, and the remaining 21% either unknown/other with no difference in genotypic distribution comparing children and adults.
Description of Respiratory Virus Activity During 2003-2009
Surveillance revealed that different influenza virus types and subtypes were dominant during annual epidemics and RSV detections increased in the latter years ( Figure 1 strain was not accounted for in the analyses. Further, regional and temporal variations occurred in respiratory virus activity over the study period (data not shown).
Pulmonary Exacerbation Seasonality
A total of 12 336 pulmonary exacerbations occurred in the 2003 calendar year comprising 5396 events in children and 6940 events in adults. In the study period, there was a total of 91 291 exacerbation episodes in 31 568 individuals (Table 2) . Of these, 37 169 occurred in children and 54 122 occurred in adults. The proportion of patients with at least 1 exacerbation episode was 34%-36% annually and this was consistent over the study period. The crude incidence rate of pulmonary exacerbations was 375.2 per 10 000 person-months in children and 713.5 per 10 000 person-months in adults. Assessment of exacerbation frequency demonstrated that at least 58% of patients had ≥1 annual event, and 22% had ≥5 events (Table 2) . Approximately 86.5% of total exacerbation episodes were managed in hospitals, and a greater proportion of children were hospitalized than adults (93.4% vs 81.9%). An annual increase in pulmonary exacerbations occurred during the winter months, and pulmonary exacerbations were temporally associated with increases in influenza and RSV activity ( Figure 1 ).
Multivariate Model of Pulmonary Exacerbation
In a multivariate Poisson regression model, influenza virus activity (expressed per 10% change in test positivity) was significantly associated with pulmonary exacerbation risk in children (relative risk [RR], 1.02; 95% CI, 1.01-1.03; P < .001) and adults (RR, 1.02; 95% CI, 1.01-1.02; P < .001) after adjusting for demographic, clinical, and socioeconomic factors (Table 3) . RSV activity (percentage test positivity, per 10%) was associated with increased exacerbation risk in children (RR, 1.05; 95% CI, 1.02-1.07; P < .001) but did not achieve statistical significance in the adult cohort (RR, 1.01; 95% CI, 1.00-1.03; P = .07) ( Table 3) .
Sensitivity Analyses
We conducted sensitivity analyses in relation to covariates in our multivariate models that had a substantial number of observations (person-weeks) with missing data. Specifically, models additionally adjusted for lung function (FEV 1 predicted), median income, and BMI resulted in loss of 55% of person-weeks for the child data and 43% of the person-weeks for the adult data. The estimated effects of influenza virus activity on the pulmonary exacerbation risk from the sensitivity analysis models were similar to the results from the primary analysis models (Table 4) .
DISCUSSION
Respiratory viruses are often found in samples collected during CF-associated pulmonary exacerbations, but their clinical The above represents a multivariate Poisson regression model done as a sensitivity analysis for children and adults. Represents approximately 50% of total data due to missing data in additional covariates in the model (refer to Supplementary Methods). Effects of temporal adjustments that were present in the multivariate model (quartic polynomial of year as well as sin and cos of 2π*year) are not shown.
Abbreviations: BMI, body mass index; CI, confidence interval; FEV 1 , forced expiratory volume in 1 second; RR, relative risk; RSV, respiratory syncytial virus.
importance remains understated and poorly understood [12] . Diagnostic test limitations, study designs, and emergence or presence of novel or established bacterial pathogens, respectively, in CF patient airways have contributed to the challenges in determining the specific role of viral pathogens in CF pulmonary disease progression [8, 11, 31] . Thus, we utilized a population-based approach with individual and community-level data to identify the association of influenza and RSV with risk of pulmonary exacerbations in individuals with CF during a 63-month period in the United States. Herein we demonstrated that regional influenza activity had a significant association with risk of pulmonary exacerbations in children and adults with CF, and RSV had a similar association in children with CF. These associations were significant even after accounting for known clinical and socioeconomic confounders supporting the role of respiratory viruses in pulmonary exacerbation events.
To our knowledge, our study is the first of its kind to assess respiratory virus disease burden within a patient registry, facilitating individual-level analyses and the adjustment for clinical predictors of severe respiratory disease. Our results regarding the impact of influenza and RSV on CF pulmonary exacerbations adds to our understanding of the potential causative roles of these respiratory viral pathogens have on lung disease progression. Our dataset was massive (>150 000 observations describing approximately 34 000 persons followed weekly for over 6 years), and we had extremely high precision to measure influenza and RSV-associated events while adjusting for potential confounding variables including presence and severity of risk factors for CF pulmonary exacerbation. As studies of this size are not feasible in many chronic lung disease populations (ie, chronic obstructive pulmonary disease) wherein increased risk of respiratory virus illness exists [32] [33] [34] , our study may serve as a risk model to guide future preventive strategies for persons with severe chronic lung disease in general.
Influenza-associated illnesses are a significant threat on a global scale, and influenza has been associated with an average of 28 000 severe illness hospitalizations and 36 000 deaths annually in the United States alone [26, 35] . Increased risk of influenza illness and death has been demonstrated in persons with chronic lung disease including CF [9] . While influenza pneumonia may directly cause CF lung exacerbations, it is relatively rare in the general population [36] . Furthermore, influenza virus infection is associated with secondary bacterial infections and may alter lung flora in CF initiating pulmonary exacerbations [8, 11, 13] . Either process may be averted by vaccination.
When influenza vaccination rates were assessed in the CF population, they were lower than recommended goals, suggesting that a portion of influenza illnesses may be prevented by further efforts to improve influenza vaccine coverage [37, 38] . However, influenza vaccine effectiveness is typically only moderate in magnitude, and during the study period it ranged from 33% to 67% in the United States [39] . With these effectiveness estimates, vaccine failures during the study period would not have been uncommon. We have previously demonstrated that persons with CF who have ≥4 pulmonary exacerbations annually have nearly an order of magnitude greater risk for influenza-associated pulmonary exacerbations compared with the overall cohort [9] . Given the elevated risk for this subgroup of persons with CF, chemoprophylaxis with neuraminidase inhibitors against influenza virus infection should be considered during the influenza season [40] .
Similarly, RSV has been attributed to significant morbidity, especially in infants and children [10, 15] . Our study supports this finding as RSV had a significant association with pulmonary exacerbation risk in the children cohort. Pavilizumab, a monoclonal antibody vaccine, did not demonstrate significant efficacy for RSV infection in children with CF in a single clinical trial despite having benefit in reduction of hospitalization in other high risk populations [41] . Purified fusion protein vaccines have also been studied in CF pediatric cohorts to prevent RSV infection, without demonstrable efficacy [42, 43] . Given the trend we saw with RSV-associated adult pulmonary exacerbations, it is possible that particular subsets of adults with frequent pulmonary exacerbations are at significantly increased risk and should be considered for future vaccines or next-generation RSV monoclonal antibodies.
Although our study was a large CF population-based study spanning several years, it has limitations to consider. We used ecologic linkages between CF outcomes and regional respiratory virus activity. Typically, studies to assess the burden of respiratory virus disease are ecologic comparisons of aggregated events data from administrative databases and surveillance data over time [9, 35, 44] . While ecological in nature, our study incorporated patient-level predictors of pulmonary exacerbations, thus strengthening our measures of association. As our influenza and RSV data were obtained from the CDC surveillance databases, we did not have access to respiratory virus laboratory test results from persons in our cohort or the ability to confirm influenza or RSV infections in relation to exacerbation events. In this regard, as the diagnosis of pulmonary exacerbations is clinician based, we relied on the accuracy of the CFFPR data. Influenza vaccination and RSV prophylaxis data were not incorporated, as these data were not consistently or at all available during the study period. We did not study other respiratory viral pathogens found in CF pulmonary infections such as rhinovirus or human metapneumovirus, as available surveillance data were not as comprehensive. Sputum bacteriology was not incorporated as only data for P. aeruginosa were available, and we sought to confirm our earlier findings regarding influenza in CF [9] . Due to the study design with weekly data for analysis, there was a possibility of duplicate counting of pulmonary exacerbation events, although we attempted to exclude them. However, if there was duplicate counting of exacerbation events, and if they occurred at random, this would have biased results toward the null as influenza and RSV seasons only overlapped by approximately one-third of each year. In conclusion, our population-based study demonstrated that both influenza and RSV have a significant association with pulmonary exacerbation risk even after accounting for important confounders in individuals with CF. Given the potential deleterious effects of viral pathogens in CF, exploration of novel vaccines or chemoprophylactic strategies in this population is warranted.
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